Microbiome Innovation Centre visits TriRx Speke Facility
Last week members of the Microbiome Innovation Centre (MIC), visited TriRx's Speke facility as part of an ongoing commitment to develop and strengthen the microbiome innovation ecosystem in Liverpool City Region.
TriRx is a contract development and manufacturing organisation headquartered in the US with UK facilities based in Liverpool. Members of the MIC were given a tour of the development lab and biotech area of the Speke facility, which spans 42 acres and houses human and animal health capabilities including biotech API production and one of the largest fermentation facilities in Europe.
Professor Jo Fothergill, Director of MIC said: "Part of the remit of the MIC is to facilitate and accelerate the development of novel microbiome therapeutics through access to expert academic consultancy and cutting-edge technology. Strong partnerships with local manufacturing partners such as TriRx, mean that we can support innovators to develop their products with the end in mind as well as provide appropriate signposting, where relevant. We look forward to working more closely with TriRx in this endeavour."
David Cosgrove, Senior Director at TriRx commented: "TriRx is dedicated to strengthening the life science capabilities of the Liverpool City Region and has committed an initial £10m investment in a new monoclonal antibody facility as part of the Liverpool City Region’s Investment Zone programme. Strengthening relationships with key local partners will be key to showcasing our capabilities and creating jobs and impact in the region. We are therefore really enthused by our developing partnership with the Microbiome Innovation Centre and look forward to future collaborations with the centre and the University more broadly."